Physician profile
Leon Kohanbash
NPI 1295914869
$6,034.80
in general payments reported to CMS, 2019-2025
22 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $694 · 2023: $954 · 2024: $1,350 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.57 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $808.02 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $772.98 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $631.63 | 2021-2023 | Wegovy |
| Lilly USA, LLC | $598.43 | 2021-2025 | Mounjaro |
| Abbvie INC. | $556.42 | 2021-2025 | |
| Genzyme Corporation | $392.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.58 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $375.00 | 2021-2022 | |
| Janssen Biotech, INC. | $300.00 | 2025 | Tremfya |
| Exact Sciences Corporation | $241.62 | 2023-2025 | Cologuard Collection Kit |
| Intuity Medical INC | $207.71 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astellas Pharma US INC | $200.32 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $178.96 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.07 | 2022-2025 | Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.74 | 2022-2024 | Xifaxan, Trulance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $57.27 | 2021-2023 | Shingrix, Bexsero, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.16 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $37.63 | 2023-2025 | Gvoke Hypopen |
| Sk Life Science, INC. | $33.14 | 2022 | |
| Seqirus USA INC | $29.03 | 2025 | Fluad, Flucelvax |
| Tandem Diabetes Care, INC. | $25.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Idorsia Pharmaceuticals US INC | $23.43 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Kohanbash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.